Has the public and political outcry regarding drug price hikes had any effect on the pharmaceutical industry?
On one hand, Michael Pearson, the outgoing CEO of Valeant, one of the pharmaceutical companies that Congress is scrutinizing over its dramatic price hikes, is expected to issue a mea culpa Wednesday in testimony before a Congressional panel over his company's pricing strategy.
"I recognize that we therefore need to work to regain the confidence of Congress, the public, doctors and patients," Pearson will say, according to prepared remarks released to media.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
